Clinical Research Directory
Browse clinical research sites, groups, and studies.
Evaluate the Efficacy and Safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus Patients
Sponsor: Chong Kun Dang Pharmaceutical
Summary
The purpose of this study is to evaluate the efficacy and safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus Patients
Official title: A Multi-center, Randomized, Open-label, Active Comparator-controlled, Phase 4 Clinical Trial to Evaluate the Efficacy and Safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus Patients Inadequately Controlled With Metformin and Sitagliptin
Key Details
Gender
All
Age Range
19 Years - Any
Study Type
INTERVENTIONAL
Enrollment
200
Start Date
2026-03
Completion Date
2027-08
Last Updated
2026-01-26
Healthy Volunteers
No
Conditions
Interventions
empagliflozin 10mg
once a day for 24 weeks
Glimepiride 1mg
once a day for 24 weeks
Locations (1)
Kyung Hee University Hospital at Gangdong
Seoul, South Korea